Rebirth of the God-level Xueba

After reading the materials all night, Fan Lundin pretended to be very confident and came to Huarui Lab. .

He is a medicinal chemist and biologist with a professional background, but the more he is like this, the more he knows the challenges he may face, just like all medicinal chemists and biologists face when they first contact a new project As a challenge, Van Lundin knew that what he would face was a vast amount of biological literature and related basic principles.

The researchers of any company, when they are going to make a certain drug, the first thing they need to do is to consult a large amount of literature.

In Zeneca, researchers usually use three rooms to fill materials, read them all, and make notes.

If you're going to have your company spend millions of dollars to start a project, and expect to spend hundreds of millions, then you'd better be prepared to die.

Don't look at the relaxed expression when talking with Arnold, but Fan Lundin still dared to come to see Yang Rui after staying up all night to make up for it.

"Mr. Yang Rui." Fan Lundin came to Huarui Laboratory and greeted the Chinese researchers very politely.

Fan Lundin has read Yang Rui's article, and Fan Lundin has also studied Yang Rui's coenzyme q10 design.

Although he didn't want to admit it, Fan Lundin originally joined the industry because of his lack of research talent. Let alone Yang Rui, who is at the top level in academia, even a master at an ordinary level, Fan Lundin has to pay attention to his wording.

He didn't want to be caught in the wrong place by Yang Rui, so that he was laughed at.

The lack of familiarity with deferiprone is what Van Lundin considers to be the key flaw. Therefore, after saying hello, Van Lundin hurriedly said: "I heard that you are not clear about the process of new drug development. I have participated in an immature project before. Hope that helps."

"Of course you can help, come in quickly. We just need you." Yang Rui greeted warmly. What he needs most now is a guide, even if he is a blind person, as long as he can tap the correct path with a stick, Yang Rui will be very happy.

Valentin was a little guilty, but also somewhat complacently asked: "How far have you made it?"

"We are still synthesizing more active substances. I think it would be better to have a few more backups." Yang Rui has no need to hide.

Van Lundin slowly entered the state, and said: "That's right, the more active substances there are, the greater the chance of finally getting the finished product."

Ordinary small companies usually just prepare two or three active substances. Their goal is not to make new drugs, but to sell them to large companies after animal experiments or the first phase of clinical trials.

Large pharmaceutical companies prepare more active substances, usually more than 20 kinds. Companies like Pfizer often prepare more than 50 kinds of active substances. The final result, such as Pfizer, often has a backup compound and a main compound that pass the FDA's review, thus turning one drug into two drugs.

This is a winner-take-all industry. Most small companies cannot last for 36 months, and large pharmaceutical companies do not always get what they want. Super pharmaceutical companies such as Pfizer are faced with high costs. The average cost of developing a new drug is 700 million U.S. dollars, far exceeding the industry average of 200 million U.S. dollars.

Compared with generic drugs that often cost only a few million yuan, the depth of the bottomless pit of original drugs cannot be measured.

Fan Lundin decided to persuade Yang Rui to do more active substances first, then conduct more animal experiments, and then conduct more clinical trials. If there are no results at this point, the average pharmaceutical company will be finished.

The chances of not getting results are very high.

"The project team I was in before was mainly to develop antibiotics, but it failed unfortunately. If I say that I still have experience, it is to give a relatively generous estimate of the possible problems in the experiment." Keto go on, but only talk about my own experience,

So as not to show cowardice.

Yang Rui agreed: "It is very useful to be generous. How far have you made it?"

With exactly the same problem as Arnold, Van Lundin said: "The second phase of the clinical trial did not succeed."

"Unfortunately."

"It is related to our initial plan. You know, antibiotics are actually relatively easy to develop drugs, because the effectiveness of drugs can be tested in vitro, so no one thought that the second phase of clinical trials would fail." Van Lundin said and introduced Some situations within the project team.

Yang Rui, Wei Zhenxue and others nodded while listening. This is indeed a rare experience.

After a while, Wei Zhenxue asked even more strangely: "You also said just now that the effectiveness of antibiotics can be learned in the laboratory without human testing. Before you do animal experiments, you should know whether it is effective or not. , how could the second phase fail?"

"We didn't predict that it is a temperature-sensitive compound. Once a patient has a high fever, its effectiveness will be greatly attenuated." Van Lundin shrugged with embarrassment on his face.

Wei Zhenxue laughed without hesitation.

This is indeed a very stupid way to fail.

Huang Mao said consolingly, "There's nothing you can do if you're unlucky."

Van Lundin's embarrassment disappeared in a flash, and he continued: "There are too many problems encountered in the clinical trial. Although I would like to admit that it is due to luck, compared with the successful project team, I think it is our lack of preparation in the early stage."

"Oh, what do you mean?"

"First of all, there is no backup compound." Van Lundin said that compounds with the same target but different structures, such as deferoxamine and deferiprone, have such a relationship. This hierarchical structure is more powerful than multiple active substances. .

Yang Rui shook his head: "We can't afford it."

Of course Valentine knew they couldn't afford it, and it wasn't the small companies that could afford it.

Van Lundin nodded: "Our project team also wanted to save this money and use it to increase the success rate of a compound. I have to say that we were very optimistic about that compound back then. No one expected it. In the end, we will encounter temperature. Sensitive situation."

"Didn't you do an experiment in advance?" Huang Mao asked.

"The performance of in vitro experiments is not obvious, but the environment in the human body obviously increases its sensitivity."

"This is something unexpected." Yang Rui nodded heavily. He was also worried about this kind of thing happening. In other words, every project director was worried about this kind of unexpected thing happening. Man is not a god. Any exploration into a new field , Everyone prays for good luck, and when bad luck is entangled, everyone will rush to the street.

"Yes, so our project team was disbanded if the second phase of the clinical trial failed." Van Lundin paused for a while, and then said: "In fact, there are many reasons for the failure, and the lack of backup drugs is just one of them. Too little active substance is also a big problem."

"How many active substances have you synthesized?" Wei Zhenxue naturally followed his words.

"6 types. Our project team is not very valued, because it has been reorganized once, and its competitiveness is not as good as other projects, so it is relatively tight, and there are fewer active substances synthesized. As a result, there are fewer active substances that pass animal experiments. At that time, there was no choice, and there was a problem in the second phase of the clinical trial, and there was no backup, so we could only announce the failure of the project..." Fan Lundin told the truth, without a single lie.

There is such a disadvantage in that the synthetic active substances are few. Although the number of 6 active substances is slightly more than that of the small company, it is still poor enough. Normal small pharmaceutical companies do not think about passing the second or even third phase of clinical trials, and their capital does not allow them to invest so much.

Wei Zhenxue asked with a slightly changed face: "You have prepared a total of 6 active substances, all of them?"

Fan Lundin thought that he had frightened Wei Zhenxue, and quickly explained: "We have been working for nearly a year, and everyone was exhausted. At that time, our synthesis work was not going well, so we finally prepared 6 kinds. If your goal is to produce a finished drug of deferiprone, I think the standards for the six active substances are not high.”

"Of course not." Wei Zhenxue muttered.

"Huh?" Valentine didn't quite understand.

"We've already made 12 kinds, exactly double what you said." Wei Zhenxue curled his lips and said, "Yang Rui plans to continue."

"I agree with your point of view. The preliminary preparation must be sufficient." Yang Rui does not know pharmaceuticals, but he knows the research direction of deferiprone. Therefore, it is necessary to make a large number of active substances with deferiprone structure and cover them as comprehensively as possible. The most correct choice.

Fan Lundin prepared a full stomach of persuasion words, and once he started, he was useless... His goal had been achieved, but looking at Yang Rui's confident expression and the positive atmosphere in the laboratory, Fan Lundin felt inexplicably sad.